Cargando…

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update

The emergence of different variants of SARS-CoV-2, including the Omicron (B.1.1.529) variant in November 2021, has resulted in a continuous major health concern at a global scale. Presently, the Omicron variant has spread very rapidly worldwide within a short time period. As the most mutated variant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohapatra, Ranjan K., El-Shall, Nahed A., Tiwari, Ruchi, Nainu, Firzan, Kandi, Venkataramana, Sarangi, Ashish K., Mohammed, Teroj Abdulrahman, Desingu, Perumal Arumugam, Chakraborty, Chiranjib, Dhama, Kuldeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897647/ https://www.ncbi.nlm.nih.gov/pubmed/35594528 http://dx.doi.org/10.1080/21645515.2022.2065824

Ejemplares similares

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
por: Khandia, Rekha, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic – Correspondence
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants
por: Wu, Dan, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
por: Zhao, Hanjun, et al.
Publicado: (2022)

Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
por: Paul, Pradipta, et al.
Publicado: (2023)

Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review
por: Du, Yuxuan, et al.
Publicado: (2022)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants
por: Zhao, Hanjun, et al.
Publicado: (2022)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants
por: de La Vega, Marc-Antoine, et al.
Publicado: (2023)

SARS-CoV-2 gained a novel spike protein S1–N-Terminal Domain (S1-NTD)
por: Desingu, Perumal Arumugam, et al.
Publicado: (2022)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas
por: Jia, Hongling, et al.
Publicado: (2022)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
por: Sarkar, Aparajita, et al.
Publicado: (2023)

Intranasal infection by SARS-CoV-2 Omicron variants can induce inflammatory brain damage in newly weaned hamsters
por: Li, Can, et al.
Publicado: (2023)

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
por: Bingula, Rea, et al.
Publicado: (2023)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

A comparative analysis exposes an amplification delay distinctive to SARS-CoV-2 Omicron variants of clinical and public health relevance
por: Brown, K.L., et al.
Publicado: (2022)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
por: Wang, Miao, et al.
Publicado: (2022)

A comparative study on the persistence and viability of SARS-CoV-2 wild-type and omicron variant on artificially contaminated surfaces: the role of fomites
por: Fusco, Giovanna, et al.
Publicado: (2023)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies
por: Dhama, Kuldeep, et al.
Publicado: (2023)

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants
por: Chen, Yuxin, et al.
Publicado: (2022)

Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
por: Rissmann, Melanie, et al.
Publicado: (2022)

Recent re-emergence of Marburg virus disease in an African country Ghana after Guinea amid the ongoing COVID-19 pandemic: Another global threat? Current knowledge and strategies to tackle this highly deadly disease having feasible pandemic potential
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China
por: Yin, Zhiying, et al.
Publicado: (2023)

Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain)
por: Ciuffreda, Laura, et al.
Publicado: (2023)

Recent surge in cholera outbreaks globally during the COVID-19 pandemic era: a potential threat to the African continent and salient counteracting strategies
por: Mohapatra, Ranjan K., et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_37ggu0bc8ub7prkv80lognui8d